19th December 2025 – (Washington) U.S. President Donald Trump on Thursday signed into law a far‑reaching defence spending bill that tightens controls on American investment in Chinese technology and restricts federal contracting with Chinese biotechnology firms, against the backdrop of a fragile truce in U.S.‑China trade tensions.
The National Defense Authorization Act (NDAA), approved annually for more than six decades and often used to advance measures beyond core defence policy, cleared Congress after months of negotiations. The Senate passed the package on Wednesday by 77 votes to 20, following House approval of 312 to 112 last week.
Finalised amid a tentative easing of tariff hostilities and export controls between Washington and Beijing, this year’s NDAA includes two headline provisions: the Biosecure Act, limiting executive‑branch contracts with Chinese biotech companies, and the Foreign Investment Guardrails to Help Thwart (FIGHT) China Act, aimed at constraining U.S. outbound investment in Chinese technologies with potential military uses. Both measures have enjoyed sustained bipartisan backing.
A similar biosecurity measure was dropped last year after a Democratic lawmaker intervened over local jobs linked to one of the targeted Chinese firms.
The post Trump signs NDAA curbing U.S. investment in Chinese tech and federal biotech contracts appeared first on Dimsum Daily.
No comments yet.